

## FACULTY

Omar Abdel-Wahab, MSKCC, New York, USA  
Tiziano Barbui, Ospedali Riuniti, Bergamo, Italy  
Giovanni Barosi, IRCCS Policlinico S.Matteo, Pavia, Italy  
Olivier Bernard, Institut Gustave Roussy, Paris, France  
Alberto Bosi, University of Florence, Italy  
Mario Cazzola, University of Pavia, Italy  
Francisco Cervantes, Hospital Clinic, Barcelona, Spain  
Nicholas C.P. Cross, University of Southampton, United Kingdom  
Heinz Gisslinger, Medical University, Vienna, Austria  
Jason Gotlib, University School of Medicine, Stanford, USA  
Anthony R. Green, University of Cambridge, United Kingdom  
Paola Guglielmelli, University of Florence, Italy  
Ronald Hoffman, Mount Sinai School of Med, USA  
Robert Kralovics, Center for Molecular Medicine, Vienna, Austria  
Nicolaus Kroeger, Univ. Medical Center Hamburg, Germany  
Terra Lasho, Mayo Clinic, Rochester, USA  
Ross Levine, MSKCC, New York, USA  
Lucio Luzzatto, Istituto Toscano Tumori, Italy  
Ruben Mesa, Mayo Clinic, Scottsdale, Arizona  
Animesh Pardanani, Mayo Clinic, Rochester, USA  
Francesco Passamonti, AO Univ-Osp. di Circolo, Varese, Italy  
Vittorio Rosti, IRCCS Policlinico S.Matteo, Pavia, Italy  
Ayalew Tefferi, Mayo Clinic, Rochester, USA  
Jurgen Thiele, University of Cologne, Germany  
William Vainchenker, Institut Gustave Roussy, Paris, France  
Alessandro Maria Vannucchi, University of Florence, Italy

**Meeting location**  
Salone dei Duecento  
Palazzo Vecchio  
Piazza della Signoria, Firenze

**Scientific Secretary**  
Dr. Paola Guglielmelli  
Dr. Elisa Malevolti  
Dr. Lisa Pieri  
Dr. Maria Chiara Susini  
*Sezione di Ematologia  
Universita' di Firenze*

**Under the auspices of:**  
Associazione Italiana per la Ricerca  
sul Cancro- Progetto AGIMM  
Istituto Toscano Tumori  
Universita' di Firenze

**Thanks to:**  
Mary e Salomon Turner, U.S.A.



# **2nd Annual Florence Meeting on Myeloproliferative Neoplasms & the Annual IWG-MRT Workshop**

*Supported by an unrestricted education  
grant from Mary and Salomon Turner*

**April 21st, 2012  
Palazzo Vecchio, Florence**

<http://mpn-florence.com>



Welcome Address: 8:15-8.45

## Meeting Opening

A.M. Vannucchi

- 8.15 Mayor of Florence M. Renzi  
8.20 Dean of the Faculty of Medicine, University of Florence G.F. Gensini  
8.25 Scientific Director of the Istituto Toscano Tumori L. Luzzatto  
8.30 Director of Hematology Section, University of Florence A. Bosi  
8.35 **Mary and Salomon Turner, Benefactor**

## 1st SESSION: 8.45-10.50

### Molecular Pathogenesis

Chairs: L. Luzzatto, A.R. Green

**8.45-9.00** L. Luzzatto

**Cutting edge:** Oncogene addiction

9.00-9.25 R. Kralovics

Novel mutations

9.25-9.50 N. Cross

Predisposition alleles

9.50-10.15 W. Vainchenker

Mechanisms of genomic instability in MPN

10.15-10.50 O. Abdel-Wahab / P. Guglielmelli

T. Lasho / V Rosti

“Seven minutes” presentations of new information`

Coffee Break: 10.50-11.10

## 2nd SESSION: 11.10-12.15

### Cell biology

Chairs: G. Barosi, R Levine

**11.10-11.25**

**Cutting edge:** MPN stem cell

11.25-11.50

TET2 function in stem cells

11.50-12.15

Canonical and non-canonical roles of JAK2

12.15- 12.20

**Presentation of the “2nd MPN Medal of Honor”**

A. Tefferi, A.M. Vannucchi

**12.20-12.45**

**Keynote Address:**

The central role of histopathology for MPN diagnosis

**12.45-13.00** Discussion

Lunch: 13.00-14.00

## 3rd SESSION: 14.00-15.40

### Clinical entities and prognostic models

Chairs: F. Cervantes, A. Bosi

14.00-14.25

M. Cazzola

RARS-T

14.25-14.50

H. Gisslinger

ET and pre-fibrotic MF

14.50-15.15

T. Barbui

Prognostic model for PV

15.15-15.40

N. Kroger

Transplant versus JAK inhibitors in MPN

## 4th SESSION: 15.40-17.20

### Novel Drugs

Chairs: F. Passamonti, J Gotlib

15.40-16.05

J. Gotlib

JAK inhibitors: phase 3 trials

16.05-16.30

A. Pardanani

JAK inhibitors: phase I/II studies

16.30-16.55

R. Hoffman

HDAC inhibitors

16.55-17.20

R.A. Mesa

The interface between curative and palliate therapy in MPN

17.20 **Concluding remarks**

A. Tefferi